AXON

Axon is a genuinely high-quality franchise, and the top line proves it: revenue grew 33.5% to $2.78B in FY2025 and has compounded from $863M in FY2021 with no down years. The mix is improving toward the parts investors pay up for — services are now 43.3% of sales and the Platform Solutions line grew 72.5% — while gross margin held at 59.7%. The balance sheet is a clear strength: cash jumped 164% to $1.20B, current assets cover current liabilities ~2.5x ($3.71B vs $1.47B), and liabilities/equity is a manageable 1.16x. This is not a broken business.

The problem is earnings quality. GAAP operations just flipped to a $62.1M loss (-2.2% margin) from +$58.5M a year ago, as operating expenses rose $537.4M on headcount and stock-based comp — R&D alone climbed 55% to $684M and SG&A reached 37.3% of sales. The reported $125M of net income is heavily flattered: MD&A discloses $186.4M of net gains on strategic investments plus a $105.7M income-tax benefit; strip those out and there is essentially no operating profit underneath. Operating cash flow fell 48% to $211M, and shares grew 4.9% from ongoing dilution. So the headline 280x P/E sits on earnings that are mostly non-operating.